Follow-up study of repeat stem cell injections for brain condition
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study is a follow-up for people who already received one dose of an experimental stem-cell treatment (called RB-ADSC) for a brain condition. It tests whether giving additional doses through a small tube in the brain is safe and tolerable. If you did well in the first study, this might be an option for continued treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the earlier study that tested a single dose of this treatment.
- You must have a caregiver or relative who can watch for side effects after each injection.
- Your caregiver must also meet the study's requirements for caregivers.
- You must not have had serious side effects related to the treatment in the earlier study.
- The study doctor must agree that you are suitable for this follow-up study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new treatment for people with mild to moderate Alzheimer's disease. They take your own fat cells, turn them into stem cells, and inject them into the fluid around your brain. The hope is that these cells may help slow down memory loss.
This trial tests whether stem cells from donated fat tissue can help people with mild to moderate Alzheimer's disease. It combines infusions of these cells with standard care, and includes brain scans and memory tests to see if the treatment is safe and effective.
This study tests whether bone-marrow stem cells can improve nerve function in people with nerve damage that usually doesn’t recover with current care. It also checks whether the treatment is safe and whether people can be followed over time with repeated nerve exams.
This trial continues treatment for people who finished the earlier SNK01-AD01 study. It tests a personalized cell therapy (SNK01) to see if ongoing treatment is safe and helpful for Alzheimer's disease.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This trial tests a stem cell treatment for people with early-stage Alzheimer's disease. It aims to see if the treatment can help slow memory loss or other symptoms. You must have a specific blood test showing inflammation in the body to qualify.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.